Brokers Set Expectations for FULC FY2029 Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Investment analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Fulcrum Therapeutics in a research report issued on Wednesday, February 26th. HC Wainwright analyst A. Fein anticipates that the company will post earnings per share of ($0.95) for the year. HC Wainwright currently has a “Neutral” rating and a $4.00 price target on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share.

Separately, Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $9.33.

Fulcrum Therapeutics Stock Down 10.3 %

FULC opened at $3.32 on Thursday. The business’s fifty day simple moving average is $4.13 and its 200 day simple moving average is $4.62. Fulcrum Therapeutics has a 52 week low of $2.86 and a 52 week high of $13.70. The firm has a market cap of $179.08 million, a P/E ratio of -10.71 and a beta of 2.03.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03).

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of large investors have recently modified their holdings of the company. Bank of New York Mellon Corp raised its holdings in shares of Fulcrum Therapeutics by 2.3% in the 4th quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company’s stock worth $667,000 after purchasing an additional 3,126 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Fulcrum Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock worth $43,000 after purchasing an additional 4,701 shares during the period. American Century Companies Inc. raised its holdings in shares of Fulcrum Therapeutics by 5.9% in the 4th quarter. American Century Companies Inc. now owns 120,611 shares of the company’s stock worth $567,000 after purchasing an additional 6,770 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of Fulcrum Therapeutics in the 4th quarter worth about $38,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Fulcrum Therapeutics by 34.4% in the 4th quarter. Wells Fargo & Company MN now owns 34,264 shares of the company’s stock worth $161,000 after purchasing an additional 8,761 shares during the period. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.